VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...
VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...
VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
LONG TERM FOLLOW UP OF POOR PROGNOSIS STAGE IV BREAST<br />
CANCER PATIENTS TREATED WITH TWO COURSES OF HIGH-DOSE<br />
CHEMOTHERAPY AND BONE MARROW SUPPORT<br />
Frank Dunphy, Gary Spitzer, Jonathan Yau, Susan Huan, Jorge Spinolo,<br />
Sundar Jagannath, Ralph Wallerstein, Karel Dicke, Aman Buzdar,<br />
Gabriel Hortobagyi<br />
From the Division of <strong>Bone</strong> <strong>Marrow</strong> <strong>Transplantation</strong>, Medical Oncology,and<br />
Hematology (FD, GS), Department of Internal Medicine, Saint Louis University<br />
Medical Center, St. Louis, MO 63110-0250; and the Department of Hematology<br />
(JY, SH, JS, SJ, RW, KD) and Breast Medical Oncology (AB, GH), The University<br />
of Texas M. D. Anderson Cancer Center, Houston, Texas 77030.<br />
Address reprint requests to:<br />
Frank Dunphy, ME)<br />
Saint Louis University Medical Center<br />
Division of <strong>Bone</strong> <strong>Marrow</strong> <strong>Transplantation</strong>,<br />
Medical Oncology, and Hematology<br />
3635 Vista Ave. at Grand Blvd.<br />
P.O. Box 15250<br />
St. Louis, MO 63110-0250<br />
INTRODUCTION<br />
Stage IV breast cancer patients who are estrogen receptor-negative (ER-) or<br />
estrogen receptor-positive (ER+) "refractory" to hormonal manipulation represent<br />
a poor prognosis subgroup which behaves in an aggressive manner with a<br />
short survival and few protracted disease-free survivors. With conventional chemotherapy<br />
the median survival of this subgroup is 15-18 months, with a 10%<br />
three-year progression-free and overall survival. 0<br />
"*'<br />
We describe long term follow up data in this poor-risk subgroup of breast<br />
cancer patients. They were initially treated with conventional induction chemotherapy<br />
followed by intensificationwith two courses of high-dose cyclophosphamide<br />
4.5-6g/m 2<br />
/course; etoposide 750-1500mg/m 2<br />
/course; cisplatin 120-<br />
180mg/m 2<br />
/course. We include data of response rates, duration of response, survival,<br />
and toxicity.<br />
Patient Population and Treatment Plan<br />
Eighty stage IV ER- or ER+ "primary hormonal refractory" breast cancer<br />
patients were treated between May, 1985 and August, 1990. All patients were in<br />
first relapse. Patients were initially treated for stage IV disease with conventional<br />
combination chemotherapy (Induction Phase) to the point of maximal response.<br />
Patients with stable or responding disease then received high-dose therapy (Intensive<br />
Phase)(Fig.l). Forty-four patients were randomized to receive marrow<br />
infusion. Thirty-six were randomized to the no-marrow arm.<br />
118 SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION